Belgian Personal Products Stock News

The European market has shown resilience, with the pan-European STOXX Europe 600 Index rising by 1.03% amid expectations of a U.S. Federal Reserve interest rate cut, signaling optimism in the region's economic outlook despite some mixed signals from key economies such as Germany and the UK. In this environment, identifying high growth tech stocks involves looking for companies that are not only innovating but also effectively navigating current macroeconomic challenges and leveraging...

Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...

Ekopak NV ( EBR:EKOP ) shares have had a horrible month, losing 31% after a relatively good period beforehand. For any...

One thing we could say about the analysts on Banqup Group SA ( EBR:BANQ ) - they aren't optimistic, having just made a...

Hoogheemraadschap De Stichtse Rijnlanden recently announced that the Lekensemble consortium, comprised of DEME, Heijmans, and GMB, has secured a contract to reinforce the Lekdijk between Wijk bij Duurstede and Amerongen in the Netherlands, as part of the national Dutch Flood Protection Program. This contract highlights DEME's growing role in large-scale climate adaptation infrastructure, reinforcing its capabilities in critical water management projects that safeguard communities. We'll...

Agfa-Gevaert NV ( EBR:AGFB ) shareholders won't be pleased to see that the share price has had a very rough month...

Immobel ( EBR:IMMO ) First Half 2025 Results Key Financial Results Revenue: €148.3m (up 33% from 1H 2024). Net income...

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

If you are eyeing BGL BNP Paribas and wondering whether now is the moment to act, you are in good company. For months, investors have watched the stock hold steady at €89.00, with price change at 0.0% across one week, one month, and even year-to-date. That kind of calm may seem unremarkable at first, but in today’s often turbulent markets, stability can hint at untapped potential or simply a rebalancing of risk perceptions among those in the know. Is the market underestimating this company’s...

Thinking about what to do with Solvac stock? You are not alone. With market chatter swirling and fresh data at our fingertips, a lot of investors are taking another look at this stock and weighing whether it’s time to buy, hold, or move on. Over the past five years, Solvac’s share price has climbed 18.3%, though this year has been rougher, with the stock down 8.3% year-to-date. Short-term trends show a mild dip of 2.6% this week and a 1.7% slide in the past month, adding to some investor...

Thinking about what to do with your Fagron shares, or maybe just eyeing the stock with curiosity? You are not alone. With the price sitting at €20.8 after a year where it returned 10.3%, investors are rightly weighing whether this specialist in pharmaceutical compounding has more room to run. In fact, if you zoom out, the stock has climbed 60.4% over the past three years and 24.1% just year-to-date. Recent weeks have been more muted, with a dip of -1.2% over seven days and a modest 0.5% gain...

If you are holding KBC Ancora shares or wondering whether now is the time to buy, you are in good company. The stock has been on quite a journey, recently notching a 3.1% gain over the last week and an impressive 31.2% jump year to date. Take a look further back and you will notice the long-term momentum is striking. The stock price has more than doubled over three years and soared by nearly 215% during the past five years. These kinds of numbers catch investors’ eyes, but they also prompt an...

Thinking about what to do with Warehouses De Pauw stock? You are not alone. Investors weighing their next move have plenty to consider, especially after watching the company’s share price travel a rather unpredictable path. Over the last year, shares are down 12.7%, and if we pull the lens back further, the five-year drop stands at 22.7%. However, here is where things get interesting: the stock is actually up 11.3% year-to-date, which hints that sentiment could be shifting or that the...

If your finger is hovering over the buy or sell button for ageas, you are not alone. With insurance stocks in the spotlight and ageas itself reporting 33.5% growth over the past year, every investor is trying to determine whether this is simply a lucky streak or something more sustainable. Year to date, ageas has gained an impressive 25.4%, and over the last five years, the stock has more than doubled. However, the past month's dip of 5.1% shows that a smooth ride is never guaranteed. Some of...

Sofina Société Anonyme (ENXTBR:SOF) has been turning heads lately, and not because of a major headline or game-changing announcement. Sometimes, stocks move for reasons that seem subtle on the surface—maybe there’s a shift in sentiment, or investors are taking a closer look at where the company fits into a changing market. For anyone trying to decide whether now is the right time to act, these unexplained moves can be just as intriguing as the big news events. Zooming out, Sofina Société...

Thinking about what to do with VGP stock right now? You are definitely not alone. With market chatter picking up and investors re-evaluating their portfolios in light of shifting trends, VGP is starting to show up on more radar screens. The stock has not been especially volatile on a weekly or monthly basis, with returns of just 0.2% and 1.6%. However, over a longer term things get interesting. Over the past year, VGP edged up 1.1%. Since the start of the year, it has surged nearly 30%. None...

If you have been eyeing Tessenderlo Group stock and wondering whether to hold, buy, or move on, you are far from alone. The company’s share price sits at €26.00 after showing a modest 0.4% lift in the past week, though it dipped by 1.7% over the last month. Zoom out further, and you will notice a 35.1% surge since the start of the year, reflecting renewed optimism or shifts in perceived risk among investors. While the one-year return is up 7.8%, the longer-term picture includes a few...

Key Insights Significant control over KBC Group by private companies implies that the general public has more power to...

BGL BNP Paribas (ENXTBR:009789111) might not have set the stock market buzzing this week, but the lack of any dramatic price moves can be equally revealing for investors weighing their next step. When a stock stands still, as BGL BNP Paribas has recently, it often prompts some healthy investor curiosity about what is, and isn’t, being priced in right now. Is this quiet spell just a case of business as usual, or is the market settling in before something shifts? Looking at the bigger picture,...

If you are weighing whether to buy, sell, or simply watch Shurgard Self Storage, you are definitely not alone. The company’s recent share price movements have caught the attention of more than a few investors. Shurgard’s stock closed most recently at 32.05, and if you zoom out just a little, you will notice a clear trend: down 2.1% over the last week, off 6.8% in the past month, and down a notable 12.6% so far this year. Go back further, and the 1-year and 5-year numbers show a decline of...

If you have been watching Groupe Bruxelles Lambert (ENXTBR:GBLB) lately, the stock’s recent moves might have caught your eye. There has not been a single headline-making event this week. When a share price trends upward without a big announcement, it tends to spark questions. Is this a subtle signal from the market, or just noise? In moments like these, investors start to wonder if something is shifting beneath the surface, especially for established holding companies like Groupe Bruxelles...

Viohalco ( EBR:VIO ) Second Quarter 2025 Results Key Financial Results Revenue: €931.1m (down 62% from 2Q 2024). Net...

KBC Ancora (ENXTBR:KBCA) might not have made the front page with a headline-grabbing event today, but the recent movements in its share price are starting to catch the eye of investors who watch the Belgian financials space. Sometimes it is the quieter ticks on the chart that prompt the most interesting questions: is something brewing beneath the surface, or is the current price just a reflection of the company’s steady fundamentals? Over the past year, KBC Ancora’s stock has put in a solid...

Earlier in September 2025, argenx announced that its ADAPT SERON study for VYVGART achieved statistically significant and clinically meaningful results for treating AChR-Ab seronegative generalized myasthenia gravis, successfully meeting its primary endpoint and supporting a label expansion submission. This outcome marks a significant step for argenx, highlighting the potential to expand VYVGART's addressable market and strengthen its long-term position in the U.S. autoimmune treatment...